March 3, 2020 / 12:34 PM / a month ago

BRIEF-TG Therapeutics Expects To Report Topline Results From Phase 3 Ultimate I & II Trials In Rms, In Second Half Of 2020

March 3 (Reuters) - TG Therapeutics Inc:

* TG THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS FOURTH QUARTER AND YEAR-END 2019 FINANCIAL RESULTS

* TG THERAPEUTICS - BELIEVES ITS CASH, CASH EQUIVALENTS AS OF DEC. 31, 2019, WILL BE SUFFICIENT TO FUND CO’S PLANNED OPERATIONS WELL INTO 2021

* TG THERAPEUTICS INC - EXPECTS TO REPORT TOPLINE RESULTS FROM PHASE 3 ULTIMATE I & II TRIALS IN RMS, IN SECOND HALF OF 2020

* TG THERAPEUTICS INC - EXPECTS TO COMPLETE ROLLING NDA SUBMISSION FOR UMBRALISIB IN PATIENTS WITH PREVIOUSLY TREATED MZL AND FL, IN FIRST HALF OF 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below